Last reviewed · How we verify
TQB3473 Tablets
TQB3473 Tablets' mechanism of action is not publicly available.
At a glance
| Generic name | TQB3473 Tablets |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Unfortunately, there is limited information available on the exact mechanism of action of TQB3473 Tablets.
Approved indications
Common side effects
Key clinical trials
- A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults (PHASE2)
- A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia (PHASE3)
- A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQB3473 Tablets CI brief — competitive landscape report
- TQB3473 Tablets updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI